Using nanoparticles to help people with food allergies develop tolerance
Allergen Loaded Nanoparticles for Food Allergy Tolerance
This study is working on a new way to help people with peanut and egg allergies by using tiny particles that teach their immune systems to handle these foods better, aiming for a long-lasting solution that could make living with food allergies easier.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Michigan at Ann Arbor NIH-funded |
| Lab location | 1 site (Ann Arbor, United States) |
| Project ID | NIH-10897837 on NIH RePORTER |
What this research studies
This research focuses on developing a new treatment for food allergies, specifically targeting allergies to peanuts and eggs. It aims to create nanoparticles that are loaded with specific food allergens, which can be administered to patients to help their immune systems learn to tolerate these allergens. Unlike current treatments that only alleviate symptoms, this approach seeks to induce long-term tolerance without affecting other immune responses. The research builds on previous successes in treating autoimmune diseases and aims to provide a safe, off-the-shelf therapy for food allergy sufferers.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with food allergies, particularly to peanuts or eggs.
Not a fit: Patients who do not have food allergies or those with allergies to foods not included in the study may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a groundbreaking treatment that allows individuals with food allergies to safely consume previously harmful foods.
How similar studies have performed: Previous research using similar nanoparticle technology has shown success in treating autoimmune diseases, indicating potential for success in allergy treatment as well.
Where this research is happening
Ann Arbor, United States
- University of Michigan at Ann Arbor — Ann Arbor, United States (Active)
Researchers
- Principal investigator: Shea, Lonnie D — University of Michigan at Ann Arbor
- Study coordinator: Shea, Lonnie D
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.